Beyond pharmacotherapy: Understanding the links between obesity and chronic mental illness

Canadian Journal of Psychiatry

Volumn 57, Issue 1, 2012, Pages 5-12

  Taylor, Valerie H ^a,b   McIntyre, Roger S ^b,c   Remington, Gary ^b,d   Levitan, Robert D ^b   Stonehocker, Brian ^e   Sharma, Arya M ^e  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Attention deficit hyperactivity disorder; Bipolar disorder; Cytokines; Inflammation; Major depressive disorder; Obesity; Schizophrenia; Trauma

Indexed keywords

ADIPONECTIN; GHRELIN; HYDROCORTISONE; LEPTIN; NEUROPEPTIDE Y;

ATTENTION DEFICIT DISORDER; BINGE EATING DISORDER; BIPOLAR DISORDER; BODY MASS; CHILD SEXUAL ABUSE; CIRCADIAN RHYTHM; DISEASE ASSOCIATION; EMOTIONAL ABUSE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; MAJOR DEPRESSION; MENTAL DISEASE; NEGATIVE FEEDBACK; NEGATIVE SYNDROME; NEGLECT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSITIVE SYNDROME; PREFRONTAL CORTEX; REVIEW; SLEEP DEPRIVATION; SLEEP DISORDER; SLEEP WAKING CYCLE; SOCIAL STATUS; WAIST CIRCUMFERENCE;

EID: 84863686839     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205700103     Document Type: Review

References (129)

1. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347-1360. (Pubitemid 35341298)
2. James WP. WHO recognition of the global obesity epidemic. Int J Obes (Lond). 2008;32(Suppl 7):S120-S126.
3. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63(3):207-213. (Pubitemid 34407079)
4. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160(1):112-117. (Pubitemid 36042434)
5. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7(5):424-430. (Pubitemid 41419409)
6. McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65(5):634-651.
7. Dickerson FB, Brown CH, Kreyenbuhl JA, et al. Obesity among individuals with serious mental illness. Acta Psychiatr Scand. 2006;113(4):306-313.
8. Theisen FM, Linden A, Geller F, et al. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res. 2001;35(6):339-345. (Pubitemid 33000471)
9. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259-1272.
10. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
11. Nihalani N, Schwartz TL, Siddiqui UA, et al. Weight gain, obesity, and psychotropic prescribing. J Obes. 2011;2011:893629; [Epub 2011 Jan 17].
12. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850. (Pubitemid 32979302)
13. Stewart JW, Quitkin FM, McGrath PJ, et al. Defining the boundaries of atypical depression: evidence from the HPA axis supports course of illness distinctions. J Affect Disord. 2005;86(2-3):161-167. (Pubitemid 40780028)
14. Pae CU, Tharwani H, Marks DM, et al. Atypical depression: a comprehensive review. CNS Drugs. 2009;23(12):1023-1037.
15. Carney RM, Freedland KE, Eisen SA, et al. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14(1):88-90.
16. Blumenthal JA, Williams RS, Wallace AG, et al. Physiological and psychological variables predict compliance to prescribed exercise therapy in patients recovering from myocardial infarction. Psychosom Med. 1982;44(6):519-527. (Pubitemid 13176050)
17. Haslam DW, James WP. Obesity. Lancet 2005;366(9492):1197-1209. (Pubitemid 41393598)
18. Carpenter WT Jr, Bunney WE Jr. Adrenal cortical activity in depressive illness. Am J Psychiatry. 1971;128(1):31-40.
19. Sachar EJ, Hellman L, Fukushima DK, et al. Cortisol production in depressive illness. A clinical and biochemical clarification. Arch Gen Psychiatry. 1970;23(4):289-298.
20. Plotsky PM, Owens MJ, Nemeroff CB. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am. 1998;21(2):293-307.
21. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932. Obes Res. 1994;2(5):486-508.
22. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: does cortisol play a role? Biol Psychiatry. 2004;55(1):1-9. (Pubitemid 38045427)
23. Lyytikäinen P, Lallukka T, Lahelma E, et al. Sleep problems and major weight gain: a follow-up study. Int J Obes (Lond). 2010 Jun 8; [Epub ahead of print].
24. Crispim CA, Zalcman I, Dattilo M, et al. The influence of sleep and sleep loss upon food intake and metabolism. Nutr Res Rev. 2007;20(2):195-212. (Pubitemid 350199444)
25. Munzberg H. Leptin-signaling pathways and leptin resistance. Forum Nutr. 2010;63:123-132.
26. Rosicka M, Krsek M, Matoulek M, et al. Serum ghrelin levels in obese patients: the relationship to serum leptin levels and soluble leptin receptors levels. Physiol Res. 2003;52(1):61-66. (Pubitemid 36356261)
27. Gangwisch JE, Malaspina D, Boden-Albala B, et al. Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. Sleep. 2005;28(10):1289-1296. (Pubitemid 41437890)
28. Lu XY. The leptin hypothesis of depression: a potential link between mood disorders and obesity? Curr Opin Pharmacol. 2007;7(6):648-652.
29. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84-89. (Pubitemid 36740452)
30. Pineiro R, Iglesias MJ, Gallego R, et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett. 2005;579(23):5163-5169. (Pubitemid 41318086)
31. Delaigle AM, Jonas JC, Bauche IB, et al. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology. 2004;145(12):5589-5597. (Pubitemid 39564599)
32. Wolf AM, Wolf D, Avila MA, et al. Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol. 2006;44(3):537-543. (Pubitemid 43227878)
33. Yilmaz Y. Psychopathology in the context of obesity: the adiponectin hypothesis. Med Hypotheses. 2008;70(4):902-903. (Pubitemid 351318093)
34. Soczynska JK, Kennedy SH, Woldeyohannes HO, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med. 2011;13(2):93-116.
35. Liu HC, Yang YY, Chou YM, et al. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol. 2004;150(1-2):116-122.
36. O'Brien SM, Scott LV, Dinan TG. Antidepressant therapy and C-reactive protein levels. Br J Psychiatry. 2006;188:449-452.
37. Taylor VH, MacQueen GM. The role of adipokines in understanding the associations between obesity and depression. J Obes. 2010;2010. pii: 748048; [Epub 2010 Jul 28].
38. Volkow N, Li TK. The neuroscience of addiction. Nat Neurosci. 2005;8(11):1429-1430. (Pubitemid 41573649)
39. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature. 2000;404(6778):661-671. (Pubitemid 30205071)
40. Berridge KC, Ho CY, Richard JM, et al. The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res. 2010;1350:43-64.
41. Tomasi D, Wang GJ, Wang R, et al. Association of body mass and brain activation during gastric distention: implications for obesity. PLoS One. 2009;4(8):e6847.
42. McIntyre RS, McElroy SL, Konarski JZ, et al. Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. J Clin Psychiatry. 2007;68(9):1352-1357. (Pubitemid 47524514)
43. Remington G, Foussias G, Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs. 2010;24(1):9-20.
44. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115-1121. (Pubitemid 41773510)
45. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(Suppl 1):20-27.
46. Cohn TA, Remington G, Zipursky RB, et al. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006;51(6):382-386. (Pubitemid 43854472)
47. Dasgupta A, Singh OP, Rout JK, et al. Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1202-1207.
48. Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res. 2010;121(1-3):199-202.
49. Phutane VH, Tek C, Chwastiak L, et al. Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention? Schizophr Res. 2011;127(1-3):257-261.
50. Verma SK, Subramaniam M, Liew A, et al. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry. 2009;70(7):997-1000.
51. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68(6):609-616.
52. Strassnig M, Miewald J, Keshavan M, et al. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res. 2007;93(1-3):90-98. (Pubitemid 46817931)
53. Weiser M, Knobler H, Lubin G, et al. Body mass index and future schizophrenia in Israeli male adolescents. J Clin Psychiatry. 2004;65(11):1546-1549.
54. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010;36(2):359-369.
55. Murray GK, Clark L, Corlett PR, et al. Incentive motivation in first-episode psychosis: a behavioural study. BMC Psychiatry. 2008;8:34.
56. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578-583.
57. Berle JO, Hauge ER, Oedegaard KJ, et al. Actigraphic registration of motor activity reveals a more structured behavioural pattern in schizophrenia than in major depression. BMC Res Notes. 2010;3:149.
58. Hauge ER, Berle JO, Oedegaard KJ, et al. Nonlinear analysis of motor activity shows differences between schizophrenia and depression: a study using Fourier analysis and sample entropy. PLoS One. 2011;6(1):e16291.
59. Vancampfort D, Probst M, Sweers K, et al. Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia. Acta Psychiatr Scand. 2011;123(6):423-430.
60. Vancampfort D, Sweers K, Probst M, et al. Association of the metabolic syndrome with physical activity performance in patients with schizophrenia. Diabetes Metab. 2011;37(4):318-323.
61. Nilsson BM, Olsson RM, Oman A, et al. Physical capacity, respiratory quotient and energy expenditure during exercise in male patients with schizophrenia compared with healthy controls. Eur Psychiatry. 2010 Oct 21; [Epub ahead of print].
62. Remington G, Agid O, Foussias G. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Rev Neurother. 2011;11(4):589-607.
63. Koskinen J, Lohonen J, Koponen H, et al. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 2010;36(6):1115-1130.
64. Mazzoncini R, Donoghue K, Hart J, et al. Illicit substance use and its correlates in first episode psychosis. Acta Psychiatr Scand. 2010;121(5):351-358.
65. O'Hare JD, Zielinski E, Cheng B, et al. Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. Diabetes. 2011;60(4):1055-1062.
66. Farrimond JA, Hill AJ, Whalley BJ, et al. Cannabis constituents modulate δ9-tetrahydrocannabinol-induced hyperphagia in rats. Psychopharmacology (Berl). 2010;210(1):97-106.
67. Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011;342:d738.
68. Leeson VC, Harrison I, Ron MA, et al. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull. 2011 Mar 9; [Epub ahead of print].
69. Muller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother. 2008;8(7):1037-1048. (Pubitemid 351962072)
70. Fernandez-Ruiz J, Hernandez M, Ramos JA. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther. 2010;16(3):e72-e91.
71. Buckley PF, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383-402.
72. Romm KL, Rossberg JI, Berg AO, et al. Depression and depressive symptoms in first episode psychosis. J Nerv Ment Dis. 2010;198(1):67-71.
73. Harrow M, Yonan CA, Sands JR, et al. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull. 1994;20(2):327-338. (Pubitemid 24171095)
74. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull. 1999;25(1):157-171. (Pubitemid 29104379)
75. Wassink TH, Flaum M, Nopoulos P, et al. Prevalence of depressive symptoms early in the course of schizophrenia. Am J Psychiatry. 1999;156(2):315-316. (Pubitemid 29077126)
76. Bradley AJ, Dinan TG. A systematic review of hypothalamic-pituitary- adrenal axis function in schizophrenia: implications for mortality. J Psychopharmacol. 2010;24(4 Suppl):91-118.
77. Arranz B, Rosel P, Ramirez N, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry. 2004;65(10):1335-1342.
78. Wang HC, Yang YK, Chen PS, et al. Increased plasma leptin in antipsychotic-naive females with schizophrenia, but not in males. Neuropsychobiology. 2007;56(4):213-215. (Pubitemid 351567539)
79. Sentissi O, Epelbaum J, Olie JP, et al. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull. 2008;34(6):1189-1199.
80. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49(11):753-760. (Pubitemid 40094948)
81. Aro S, Aro H, Keskimaki I. Socio-economic mobility among patients with schizophrenia or major affective disorder. A 17-year retrospective follow-up. Br J Psychiatry. 1995;166(6):759-767.
82. Altfas JR. Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment. BMC Psychiatry. 2002;2:9.
83. Fleming JP, Levy LD, Levitan RD. Symptoms of attention deficit hyperactivity disorder in severely obese women. Eat Weight Disord. 2005;10(1):e10-e13. (Pubitemid 43098421)
84. Pagoto SL, Curtin C, Lemon SC, et al. Association between adult attention deficit/hyperactivity disorder and obesity in the US population. Obesity (Silver Spring). 2009;17(3):539-544.
85. Holtkamp K, Konrad K, Muller B, et al. Overweight and obesity in children with attention-deficit/hyperactivity disorder. Int J Obes Relat Metab Disord. 2004;28(5):685-689. (Pubitemid 38580977)
86. Agranat-Meged AN, Deitcher C, Goldzweig G, et al. Childhood obesity and attention deficit/hyperactivity disorder: a newly described comorbidity in obese hospitalized children. Int J Eat Disord. 2005;37(4):357-359. (Pubitemid 40686684)
87. Waring ME, Lapane KL. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample. Pediatrics. 2008;122(1):e1-e6.
88. Lam LT, Yang L. Overweight/obesity and attention deficit and hyperactivity disorder tendency among adolescents in China. Int J Obes (Lond). 2007;31(4):584-590. (Pubitemid 46482356)
89. Pitrou I, Shojaei T, Wazana A, et al. Child overweight, associated psychopathology, and social functioning: a French school-based survey in 6- to 11-year-old children. Obesity (Silver Spring). 2010;18(4):809-817.
90. Davis C, Levitan RD, Smith M, et al. Associations among overeating, overweight, and attention deficit/hyperactivity disorder: a structural equation modelling approach. Eat Behav. 2006;7(3):266-274.
91. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res. 2000;126:325-341. (Pubitemid 35461297)
92. Blum K, Sheridan PJ, Wood RC, et al. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics. 1995;5(3):121-141.
93. Comings DE, Gade R, MacMurray JP, et al. Genetic variants of the human obesity (OB) gene: association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene. Mol Psychiatry. 1996;1(4):325-335. (Pubitemid 126441317)
94. Levitan RD, Masellis M, Lam RW, et al. Childhood inattention and dysphoria and adult obesity associated with the dopamine D4 receptor gene in overeating women with seasonal affective disorder. Neuropsychopharmacology. 2004;29(1):179-186. (Pubitemid 38068028)
95. Kim J, Mutyala B, Agiovlasitis S, et al. Health behaviors and obesity among US children with attention deficit hyperactivity disorder by gender and medication use. Prev Med. 2011;52(3-4):218-222.
96. Harvey WJ, Reid G, Grizenko N, et al. Fundamental movement skills and children with attention-deficit hyperactivity disorder: peer comparisons and stimulant effects. J Abnorm Child Psychol. 2007;35(5):871-882. (Pubitemid 47353369)
97. Harvey WJ, Reid G, Bloom GA, et al. Physical activity experiences of boys with and without ADHD. Adapt Phys Activ Q. 2009;26(2):131-150.
98. Levy LD, Fleming JP, Klar D. Treatment of refractory obesity in severely obese adults following management of newly diagnosed attention deficit hyperactivity disorder. Int J Obes (Lond). 2009;33(3):326-334.
99. Gilbert R, Widom CS, Browne K, et al. Burden and consequences of child maltreatment in high-income countries. Lancet. 2009;373(9657):68-81.
100. Wegman HL, Stetler C. A meta-analytic review of the effects of childhood abuse on medical outcomes in adulthood. Psychosom Med. 2009;71(8):805-812.
101. Noll JG, Zeller MH, Trickett PK, et al. Obesity risk for female victims of childhood sexual abuse: a prospective study. Pediatrics. 2007;120(1):e61-e67. (Pubitemid 47036218)
102. Bentley T, Widom CS. A 30-year follow-up of the effects of child abuse and neglect on obesity in adulthood. Obesity (Silver Spring). 2009;17(10):1900-1905.
103. Chartier MJ, Walker JR, Naimark B. Health risk behaviors and mental health problems as mediators of the relationship between childhood abuse and adult health. Am J Public Health. 2009;99(5):847-854.
104. Jia H, Li JZ, Leserman J, et al. Relationship of abuse history and other risk factors with obesity among female gastrointestinal patients. Dig Dis Sci. 2004;49(5):872-877. (Pubitemid 38870217)
105. Mamun AA, Lawlor DA, O'Callaghan MJ, et al. Does childhood sexual abuse predict young adult's BMI? A birth cohort study. Obesity (Silver Spring). 2007;15(8):2103-2110. (Pubitemid 47402243)
106. Midei AJ, Matthews KA, Bromberger JT. Childhood abuse is associated with adiposity in midlife women: possible pathways through trait anger and reproductive hormones. Psychosom Med. 2010;72(2):215-223.
107. Greenfield EA, Marks NF. Violence from parents in childhood and obesity in adulthood: using food in response to stress as a mediator of risk. Soc Sci Med. 2009;68(5):791-798.
108. Hussey JM, Chang JJ, Kotch JB. Child maltreatment in the United States: prevalence, risk factors, and adolescent health consequences. Pediatrics. 2006;118(3):933-942. (Pubitemid 46090032)
109. Thomas C, Hypponen E, Power C. Obesity and type 2 diabetes risk in midadult life: the role of childhood adversity. Pediatrics. 2008;121(5):e1240- e1249.
110. Duclos M, Marquez Pereira P, Barat P, et al. Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res. 2005;13(7):1157-1166.
111. Guthrie JR, Dennerstein L, Taffe JR, et al. Central abdominal fat and endogenous hormones during the menopausal transition. Fertil Steril. 2003;79(6):1335-1340. (Pubitemid 36687879)
112. Lovejoy JC, Champagne CM, de Jonge L, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). 2008;32(6):949-958. (Pubitemid 351986225)
113. Mesch VR, Siseles NO, Maidana PN, et al. Androgens in relationship to cardiovascular risk factors in the menopausal transition. Climacteric. 2008;11(6):509-517.
114. Gibson LY, Byrne SM, Blair E, et al. Clustering of psychosocial symptoms in overweight children. Aust N Z J Psychiatry. 2008;42(2):118-125.
115. Janssen I, Craig WM, Boyce WF, et al. Associations between overweight and obesity with bullying behaviors in school-aged children. Pediatrics. 2004;113(5):1187-1194. (Pubitemid 38580679)
116. D'Argenio A, Mazzi C, Pecchioli L, et al. Early trauma and adult obesity: is psychological dysfunction the mediating mechanism? Physiol Behav. 2009;98(5):543-546.
117. Bellisle F, Blundell JE, Dye L, et al. Functional food science and behaviour and psychological functions. Br J Nutr. 1998;80(Suppl 1):S173-S193.
118. Halford JC, Harrold JA, Boyland EJ, et al. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs. 2007;67(1):27-55. (Pubitemid 46105086)
119. Agurs-Collins T, Fuemmeler BF. Dopamine polymorphisms and depressive symptoms predict foods intake. Results from a nationally representative sample. Appetite. 2011;57(2):339-348.
120. Parker G, Brotchie H. Mood effects of the amino acids tryptophan and tyrosine: 'Food for Thought' III. Acta Psychiatr Scand. 2011 Apr 12. doi: 10.1111/j.1600-0447.2011.01706.x; [Epub ahead of print].
121. Ray EC, Nickels MW, Sayeed S, et al. Predicting success after gastric bypass: the role of psychosocial and behavioral factors. Surgery. 2003;134(4):555-563; discussion 563-564.
122. Ross CA. Psychodynamics of eating disorder behavior in sexual abuse survivors. Am J Psychother. 2009;63(3):211-226.
123. Beydoun MA, Wang Y. Pathways linking socioeconomic status to obesity through depression and lifestyle factors among young US adults. J Affect Disord. 2010;123(1-3):52-63.
124. Evans DL, Charney DS. Mood disorders and medical illness: a major public health problem. Biol Psychiatry. 2003;54(3):177-180. (Pubitemid 37267845)
125. Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med. 2006;68(5):684-691. (Pubitemid 44454636)
126. Capasso A, Putrella C, Milano W. Recent clinical aspects of eating disorders. Rev Recent Clin Trials. 2009;4(1):63-69.
127. Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. Int J Obes (Lond). 2010;34(3):407-419.
128. Taylor VH, Curtis CM, Davis C. The obesity epidemic: the role of addiction. CMAJ. 2010;182(4):327-328.
129. Sansone RA, Sansone LA, Wiederman MW. The comorbidity, realtionship and treatment implications of borderline personality and obesity. J Psychosom Res. 1997;43(5):541-543. (Pubitemid 27487546)